^
    Apply
    Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) (NCT05853575)
    Phase 2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/16/2024
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib)
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596)
    Phase 2/3
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/02/2020
    Primary completion :
    10/31/2028
    Completion :
    10/31/2029
    PD-L1 • KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)
    A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway (NCT05578092)
    Phase 1/2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/02/2022
    Primary completion :
    06/30/2026
    Completion :
    07/30/2026
    EGFR • KRAS • NF1 • PTPN11
    |
    KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • MRTX0902
    Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) (KRYSTAL-2) (NCT04330664)
    Phase 1
    Mirati Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    04/07/2020
    Primary completion :
    07/29/2022
    Completion :
    02/24/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • batoprotafib (TNO155)
    KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) (NCT06026410)
    Phase 1
    Kura Oncology, Inc.
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/18/2023
    Primary completion :
    01/01/2027
    Completion :
    04/01/2027
    KRAS • NRAS • HRAS
    |
    KRAS mutation • HRAS mutation
    |
    Cabometyx (cabozantinib tablet) • Krazati (adagrasib) • KO-2806
    Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) (NCT05178888)
    Phase 1
    Mirati Therapeutics Inc.
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    01/20/2022
    Primary completion :
    06/15/2023
    Completion :
    12/30/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Ibrance (palbociclib) • Krazati (adagrasib)
    Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) (NCT04793958)
    Phase 3
    Mirati Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    06/24/2021
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Krazati (adagrasib) • leucovorin calcium
    Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers (NCT06130254)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/30/2024
    Primary completion :
    08/25/2030
    Completion :
    08/25/2030
    KRAS
    |
    Lynparza (olaparib) • Krazati (adagrasib)
    Genetic Testing in Guiding Treatment for Patients with Brain Metastases (NCT03994796)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    01/15/2025
    Initiation :
    10/17/2019
    Primary completion :
    10/01/2026
    Completion :
    06/01/2028
    KRAS • BRAF • ER • PGR • ROS1 • NTRK
    |
    HER-2 positive • EGFR mutation • HER-2 negative
    |
    Rozlytrek (entrectinib) • Verzenio (abemaciclib) • Krazati (adagrasib) • paxalisib (GDC-0084)
    Phase I Trial of Adagrasib (MRTX849) in Combination with Cetuximab and Irinotecan in Patients with Colorectal Cancer (NCT05722327)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    12/09/2024
    Initiation :
    12/06/2023
    Primary completion :
    09/30/2025
    Completion :
    09/30/2027
    KRAS • UGT1A1
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • irinotecan • Krazati (adagrasib)
    A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation (NCT06039384)
    Phase 1
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    11/28/2024
    Initiation :
    12/28/2023
    Primary completion :
    11/03/2025
    Completion :
    11/03/2025
    EGFR • KRAS • MSI
    |
    KRAS mutation • MSI-H/dMMR • KRAS G12C • RAS wild-type • KRAS G12
    |
    Krazati (adagrasib) • INCB99280
    Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab (Neo-Kan) (NCT05472623)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    11/25/2024
    Initiation :
    03/21/2023
    Primary completion :
    11/01/2025
    Completion :
    02/01/2029
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Opdivo (nivolumab) • Krazati (adagrasib)
    Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (NCT05375994)
    Phase 1/2
    Verastem, Inc.
    Active, not recruiting
    Last update posted :
    11/12/2024
    Initiation :
    08/01/2022
    Primary completion :
    12/24/2024
    Completion :
    01/01/2025
    KRAS
    |
    KRAS mutation
    |
    Krazati (adagrasib) • avutometinib (VS-6766)
    Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT) (NCT05673187)
    Phase 2
    ETOP IBCSG Partners Foundation
    Recruiting
    Last update posted :
    07/23/2024
    Initiation :
    06/12/2023
    Primary completion :
    10/01/2025
    Completion :
    03/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib)
    Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (NCT05609578)
    Phase 2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    05/24/2024
    Initiation :
    11/28/2022
    Primary completion :
    06/01/2026
    Completion :
    12/01/2026
    PD-L1 • KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)
    Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients (NCT05634525)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/15/2024
    Initiation :
    05/03/2023
    Primary completion :
    11/01/2027
    Completion :
    11/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib)
    Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) (NCT05840510)
    Phase 1/2
    Mirati Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    08/07/2023
    Primary completion :
    12/31/2025
    Completion :
    06/30/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • Fyarro (nanoparticle albumin-bound rapamycin)
    Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (NCT03785249)
    Phase 1/2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    04/11/2024
    Initiation :
    12/26/2018
    Primary completion :
    07/01/2025
    Completion :
    01/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • Gilotrif (afatinib) • Krazati (adagrasib)
    Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12) (NCT04685135)
    Phase 3
    Mirati Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    03/28/2024
    Initiation :
    04/01/2021
    Primary completion :
    12/30/2023
    Completion :
    12/01/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    docetaxel • Krazati (adagrasib)
    A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations (NCT05848843)
    Phase 1
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    01/23/2024
    Initiation :
    04/25/2023
    Primary completion :
    01/16/2024
    Completion :
    01/16/2024
    KRAS
    |
    KRAS mutation
    |
    Imfinzi (durvalumab) • Krazati (adagrasib)
    Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation (NCT05162443)
    Phase N/A
    Mirati Therapeutics Inc.
    Approved for marketing
    Last update posted :
    05/19/2023
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib)
    The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors (NCT05263986)
    Phase 1
    Zai Lab (Shanghai) Co., Ltd.
    Active, not recruiting
    Last update posted :
    02/27/2023
    Initiation :
    05/30/2022
    Primary completion :
    10/31/2023
    Completion :
    10/31/2023
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib)
    Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) (NCT04975256)
    Phase 1
    Mirati Therapeutics Inc.
    Completed
    Last update posted :
    12/08/2022
    Initiation :
    08/12/2021
    Primary completion :
    11/02/2022
    Completion :
    11/15/2022
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • BI 1701963